Condition: Multiple Sclerosis · Multiple Sclerosis (MS) - Relapsing-remitting · Sponsor: Northwestern University
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months. 2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.
This description comes directly from the study's public registry record.
Caroline Gebczak, B.S. · 630-313-0470 · caroline.gebczak@northwestern.edu
Dylan Rice, B.A. · 240-362-4800 · dylan.rice@northwestern.edu
Always discuss trial participation with your own doctor first.
| Northwestern Memorial Hospital | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07225361